DETAILED ACTION

Claims 1-2, 6, 12, 16, 29, 47-62, 68-72, 74-88, 95-107, 111-115, 117-122, 130-152 are currently pending and are present for examination. Claims 1-2, 6, 12, 16, 29, 47-48, 74-88, 101-106, 130-132 are now under consideration. Claims 49-62, 68-72, 95-100, 107, 111-115, 117-122, 133-152 remain withdrawn from consideration as being drawn to non-elected invention.

Applicants' amendments and arguments filed on 5-3-07, have been fully considered and are deemed to be persuasive to overcome the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.

Rejoinder of inventions

Claims 1-2, 6, 12, 16, 29, 74-88, 101-106, 131-132 are directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(b), claims 49-62, 68-70, directed to the process of making or using the allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104. Claims 71-72, 95-100, 107-115. 117-122, 133-147, directed to the invention(s) of the method of use of the polypeptide but not that of the polynucleotide require all the limitations of an allowable product claim (i.e., polypeptide as opposed to the polynucleotide), and therefore have NOT been rejoined.

Because a claimed invention previously withdrawn from consideration under 37 CFR 1.142 has been rejoined, the restriction requirement of groups IV, VII, and VIII only as set forth in the Office action mailed on 6-30-04 is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any

Application/Control Number: 10/081,739 Page 3

Art Unit: 1652

claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Gregory Einhorn on 5-14-07.

The application has been amended as follows:

In the claims:

- A) In claim 132, line 1, delete the word "comprising" and replace with "transformed".
- B) Please cancel claims 71-72, 95-100, 107-115, 117-122, 133-147, 148-152 without any prejudice.

Allowable Subject Matter

Claims 1-2, 6, 12, 16, 29, 47-62, 68-70, 74-88, 101-106, 131-132 are allowed.

Application/Control Number: 10/081,739 Page 4

Art Unit: 1652

The following is an examiner's statement of reasons for allowance: Following a diligent search it was determined that the prior art neither teaches nor suggests a polynucleotide with SEQ ID NO:1 having the properties and uses as claimed in claims 1-2, 6, 12, 16, 29, 49-62, 68-70, 74-88, 101-106, 131-132.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Manjunath N. Rao, Ph.D. whose telephone number is 571-272-0939. The examiner can normally be reached on 7.30 a.m. to 4.00 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1652

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Manjunath N. Rao, Ph.D.

Primary Examiner Art Unit 1652

May 14, 2007